

**GlaxoSmithKline Pharmaceuticals Limited**

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030

**PART I**

**STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 30TH SEPTEMBER, 2014**

	Unaudited					(Rs. lakhs)
	3 months ended 30.09.2014	Preceding 3 months ended 30.06.2014	Corresponding 3 months ended 30.09.2013	9 months ended 30.09.2014	9 months ended 30.09.2013	Audited Year ended 31.12.2013
Income from Operations						
Net Sales (net of excise duty)	73898	65496	62054	199379	188954	252017
Other Operating Income (net of expenses relating to service income)	778	484	611	2262	1936	2598
Total Income from Operations (net)	74676	65980	62665	201641	190890	254615
Expenses						
Cost of materials consumed	17704	13382	14912	43789	39878	53857
Purchases of stock-in-trade	14186	20545	20379	49981	50764	67000
Changes in inventories of finished goods, work-in-progress and stock-in-trade	2469	(2177)	(7806)	1778	(6242)	(5075)
Total materials consumed	34359	31750	27485	95548	84400	115782
Employee benefits expense	9950	10251	9509	28569	27328	36205
Depreciation	549	501	496	1475	1411	1988
Other expenses	14798	13807	15244	42142	42067	54921
Expenses relating to service income	(925)	(1249)	(979)	(3293)	(3289)	(4501)
Total operating expenses	24372	23310	24270	68893	67517	88613
Total expenses	58731	55060	51755	164441	151917	204395
Profit from Operations before Other Income and Exceptional Items	15945	10920	10910	37200	38973	50220
Other Income	3570	3984	3937	12042	15318	20097
Profit from ordinary activities before Exceptional Items	19515	14904	14847	49242	54291	70317
Exceptional Items	-	-	(77)	-	1774	2615
Profit from ordinary activities before tax	19515	14904	14770	49242	56065	72932
Tax Expense	6648	5075	4675	16892	17565	22744
Net Profit from ordinary activities	12867	9829	10095	32350	38500	50188
Paid-up Equity Share Capital (Face value per share Rs. 10)	8470	8470	8470	8470	8470	8470
Reserves excluding Revaluation Reserves						193249
Earnings Per Share (EPS) (of Rs. 10 each) (not annualised)						
Basic and diluted EPS (Rs.)	15.2	11.6	11.9	38.2	45.5	59.3

**PART II**

**A. PARTICULARS OF SHAREHOLDING**

Public Shareholding						
Number of shares	21175755	21175755	41785529	21175755	41785529	41785529
Percentage of shareholding	25.0%	25.0%	49.3%	25.0%	49.3%	49.3%
Promoters and promoter group Shareholding						
(a) Pledged/Encumbered						
- Number of shares	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of shares (as a % of the total share capital of the company)	Nil	Nil	Nil	Nil	Nil	Nil
(b) Non-encumbered						
- Number of shares	63527262	63527262	42917488	63527262	42917488	42917488
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%	100%
- Percentage of shares (as a % of the total share capital of the company)	75.0%	75.0%	50.7%	75.0%	50.7%	50.7%

Particulars	3 months ended 30.09.2014
<b>B. INVESTOR COMPLAINTS</b>	
Pending at the beginning of the quarter	-
Received during the quarter	8
Disposed of during the quarter	8
Remaining unresolved at the end of the quarter	-

- Net Sales of the Pharmaceuticals business grew by 20.4% during the quarter ended 30th September 2014, as compared to the corresponding quarter in the previous year. Impact of the previous year NLEM (National List of Essential Medicines) price adjustments were felt in the corresponding quarter last year.
- The Company has only one reportable segment which is Pharmaceuticals. Accordingly, no separate disclosures of segment information have been made.
- The above Results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors at their respective meetings held on 6th November, 2014.
- The statutory auditors have carried out a limited review of the standalone results for the quarter ended 30th September 2014.
- The figures for 2013 have been regrouped wherever necessary to facilitate comparison.

By Order of the Board

Dr. Hasit B. Joshipura  
Managing Director

6th November, 2014